Long-term outcomes of 170 brain arteriovenous malformations treated by frameless image-guided robotic stereotactic radiosurgery
Ramathibodi hospital experience

Pritsana Punyawai, MD\textsuperscript{a}, Nicha Radomsutthikul, MD\textsuperscript{b}, Mantana Dhanachai, MD\textsuperscript{c}, Chai Kobkitsuksakul, MD\textsuperscript{d}, Ake Hansasuta, MDE\textsuperscript{e,}\textsuperscript{∗}

Abstract
This study was conducted to report long-term outcomes of the frameless robotic stereotactic radiosurgery (SRS) for brain arteriovenous malformation (AVM) at Ramathibodi Hospital.

Retrospective data of patients with brain AVM (bAVM), who underwent CyberKnife SRS (CKSRS) at Ramathibodi Hospital from 2009 to 2014, were examined. Exclusion criteria were insufficient follow-up time (<36 months) or incomplete information. Patients’ demographics, clinical presentation, treatment parameters, and results were analyzed. Excellent outcome was defined as AVM obliteration without a new neurological deficit. Risk factors for achieving excellent outcome were assessed.

From a total of 277 CKSRS treatments for bAVM during the 6 years, 170 AVMs in 166 patients met the inclusion criteria. One hundred and thirty-nine cases (81.76\%) presented with hemorrhages from ruptured bAVMs. Almost two-thirds underwent embolization before radiosurgery. With the median AVM volume of 4.17 mL, three-quarters of the cohort had single-fraction CKSRS, utilizing the median prescribed dose of 15 Gray (Gy). In the multisession group (25.29\%), the median prescribed dose and the AVM volume were 27.5 Gy and 22.3 mL, respectively. An overall excellent outcome, at a median follow-up period of 72.45 months, was observed in 99 cases (58.24\%). Seven AVMs (4.12\%) ruptured after CKSRS but 1 patient suffered a new neurological deficit. Two patients (1.18\%) were classified into the poor outcome category but there were no deaths. Negative factors for excellent outcome, by multivariate regression analysis, were the male sex and multisession SRS delivery, but not age, history of AVM rupture, previous embolization, or AVM volume.

Despite relatively larger bAVM and utilizing a lower prescribed radiation dose, the excellent outcome was within the reported range from previous literature. This study offers one of the longest follow-ups and the largest cohorts from the frameless image-guided robotic SRS community.

Abbreviations: ARE = adverse radiation effects, AVM = arteriovenous malformation, bAVM = brain arteriovenous malformation, CI = confidence interval, CKSRS = CyberKnife stereotactic radiosurgery, CT = computerized tomography, GBM = glioblastoma multiforme, GK = Gammaknife, Gy = Gray, IQR = interquartile range, LINAC = linear accelerator, ml = millilitre, mm = millimetre, MRA = magnetic resonance angiography, mRBAS = modified radiosurgery-based score, MRI = magnetic resonance imaging, N/A = not applicable, NS = not specified, SD = standard deviation, SRS = stereotactic radiosurgery.

Keywords: arteriovenous, CyberKnife, frameless, malformation, radiosurgery, robotic, stereotactic

Editor: Jianxun Ding.
The authors report no conflicts of interest.
The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

\textsuperscript{a} Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, \textsuperscript{b} Department of Surgery, Division of Neurosurgery, King Narai Hospital, Lopburi, \textsuperscript{c} Department of Diagnostic and Therapeutic Radiology, Division of Radiation Oncology, \textsuperscript{d} Department of Diagnostic and Therapeutic Radiology, Division of Interventional Neuroradiology, \textsuperscript{e} Department of Surgery, Division of Neurosurgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

\textsuperscript{∗} Correspondence: Ake Hansasuta, Department of Surgery, Division of Neurosurgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand (e-mail: ake.han@mahidol.ac.th).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Punyawai P, Radomsutthikul N, Dhanachai M, Kobkitsuksakul C, Hansasuta A. Long-term outcomes of 170 brain arteriovenous malformations treated by frameless image-guided robotic stereotactic radiosurgery: Ramathibodi hospital experience. Medicine 2021;100:19(e25752).
Received: 9 June 2020 / Received in final form: 22 March 2021 / Accepted: 8 April 2021
http://dx.doi.org/10.1097/MD.00000000000025752
1. Introduction
Arteriovenous malformation (AVM) of the brain is a common cause of spontaneous intracranial hemorrhage in the young. Current treatment options for brain AVM (bAVM) are observation, surgical excision, endovascular embolization, and stereotactic radiosurgery (SRS).[1,2] Numerous publications, from the GammaKnife (GK) and linear accelerator (LINAC) SRS series, demonstrated the efficacy and safety of radiotherapy for bAVMs.[3–13] In contrast, data from CyberKnife (Accuray, Sunnyvale, CA) (CK) frameless image-guided robotic SRS centers were much less abundant. Colombo et al reported early results in 279 patients, treated with CK robotic SRS, with a median follow-up of 31 months. Subgroup analysis of the 102 cases, who had a follow-up duration of ≥36 months, showed an overall 71.5% rate of AVM obliteration.[14] Apart from this report, other studies by Gupta et al, Ding et al, Wowra et al, Oermann et al, and Feutren et al comprised 9, 11, 20, 26, and 48 subjects, respectively.[15–19] Thus, to furnish results from a greater number of patients with a longer follow-up period, a database of patients undergoing AVM treatment by CyberKnife SRS (CKSRS) at Ramathibodi Hospital was evaluated.

2. Materials and methods

2.1. Data collection
After approval by the Institutional Review Committee, a retrospective study of patients with bAVMs who underwent CKSRS from 2009 to 2014 was undertaken. Cases with incomplete data were excluded. Pre-SRS demographics of each patient such as age, sex, history of hemorrhage, previous AVM treatment (surgery, embolization, or radiotherapy), neurological status and clinical presentation were recorded. In those with unruptured AVMs, their initial symptom(s), such as seizure or incidental finding, were documented. Patients’ age, AVM volume, by milliliter, and location were taken into account for the calculation of modified radiosurgery-based score (mRBAS) as per the following equation: AVM score = (0.1 × volume [mL]) + (0.02 × age [year]) + (0.5 × location [0 or 1]). One point was assigned for deep locations (brainstem, basal ganglion, and thalamus), whereas 0 points were given for the non-deep areas.[20] The mRBAS were arranged into ranges of scores, ≤1, 1.01 to 1.5, 1.51 to 2 and >2, for further examination. The CKSRS treatment parameters from the included AVM were retrieved.

2.2. Radiosurgery planning and treatment technique
A moldable plastic, custom-made, mask was individually fitted for each patient before obtaining the CKSRS protocol, with 1.2 mm cuts, and a contrast-enhanced computerized tomography (CT) scan. In addition, selected series of magnetic resonance imaging (MRI) consisting of thin-sliced (1–3 mm) gadolinium-enhanced T1, proton-density, and contrast-enhanced magnetic resonance angiography (MRA) were uploaded to the CK planning station. Subsequent integration of the MRI/MRA with the CT was done. The target (AVM nidus) as well as critical structures were delineated before treatment planning. For bAVMs with a diameter <30 mm, or volume <15 mL, a single-fraction SRS was employed. For larger targets, a multi-session, in 5 daily deliveries, SRS regimen was utilized. An appropriate prescribed radiation dose, 15 to 20 Gray (Gy), was selected for the single-fraction SRS plan whereas 4 to 6 Gy/ fraction for 5 consecutive fractions was applied for the multi-session regimen. The prescribed dose was typically assigned to the 50% to 75% isodose line. A ray-tracing algorithm was exercised for dose calculation.

2.3. Outcome assessments
After the CKSRS treatment, appointments for clinical evaluation were scheduled at a 6-month interval. MRI and MRA scans at 24 or 36 months were typically obtained to determine complete obliteration of the AVM. At that time, those with apparent nidus or remaining flow, evident by early draining vein(s), were examined by annual neurologic tests, MRI, and MRA. In patients with nondetectable AVM nidus and no venous outflow by MRI/MRA, cerebral angiography would have been performed except in the event of patient refusal. For post-CKSRS assessment of outcomes, the included cases must have had at least 36 months of follow-up duration. The outcome of each patient, at his/her latest follow-up, was determined by the classification described by Pollock and Flickinger as follows: excellent, good, fair, unchanged and poor outcome, and death. Complete obliteration of the AVM without a new neurological deficit was defined as excellent outcome. Patients with AVM obliteration were classified into good outcome if they had minor deficit, and into fair outcome if they suffered major deficit that resulted in a decline of their functional status. If the AVM was not obliterated, the unchanged outcome was given to those without a new deficit while poor outcomes were patients who sustained a new deficit. Death was the last category of outcomes if it was believed to be directly related to the AVM or the SRS treatment.[21] The percentage of the aforementioned outcomes were stratified into groups based on the ranges of mRBAS,[20] as described earlier. Owing to the nature of this retrospective chart review, the clinical and radiographic outcomes, documented by multiple examiners and radiologists, were not blinded.

2.4. Data analysis
Patient, treatment, and outcome data would be presented as mean ± standard deviation (SD) or median (interquartile range [IQR]), where appropriate, for continuous variables and as percentage for categorical variables. To investigate patient and treatment factors influencing an excellent outcome, the data were compared using the Student t test or the Mann–Whitney U test for continuous variables, and the χ² or Fisher exact test for categorical variables. Univariate and multivariate analyses were utilized to identify predictors for excellent outcomes by the logistic regression model with odds ratios and 95% confidence intervals (CI) computation. Kaplan–Meier survival graph of the proportion of AVM obliteration over time would be generated by linear regression analysis. All statistical tests were performed with Stata version 14 software (StataCorp, College Station, TX). Statistical significance was considered with a P value <.05.

3. Results
From 2009 to 2014, there were 277 bAVM patients who underwent CKSRS at our institute. The excluded subjects were 22 patients whose data could not be retrieved and another 89 cases with insufficient follow-up (<36 months). This resulted in a study cohort of 166 patients, harboring 170 AVMs. Two cases
underwent CKSRS twice during the study period. Both of them had a substantial volume reduction in their AVMs but did not achieve complete obliteration. The other 2 subjects had 2 AVM nidi at different locations. A summary of the patients’ demographics is shown in Table 1. Most of the patients (81.76%) suffered AVM rupture with intracranial hemorrhage. One hundred and nine AVMs (64.12%) had endovascular occlusion before CKSRS. Approximately half of them underwent ≥2 sessions of embolization.

Table 1
Demographics of the 166 patients, 170 AVMs, who underwent CyberKnife SRS.

| Demographics                  | No. (%) |
|-------------------------------|---------|
| Age, y median (IQR)          | 26.5 (17–39) |
| Sex                           |         |
| Female                        | 94 (55.63) |
| Male                          | 72 (43.37) |
| Presentation                  |         |
| Hemorrhage (ruptured AVM)     | 139 (81.76) |
| Asymptomatic                  | 2 (1.18)  |
| Seizure                       | 29 (17.06) |
| Previous treatment            |         |
| Previous embolization         | 109 (64.12) |
| 1 Time                        | 53 (48.62) |
| 2 Times                       | 30 (27.52) |
| 3 Times                       | 13 (11.93) |
| ≥4 Times                      | 13 (11.93) |
| Previous surgery              | 7 (4.12)  |
| Previous SRS/radiotherapy     | 14 (8.24)  |

AVM = arteriovenous malformation, IQR = interquartile range, SRS = stereotactic radiosurgery, y = year.
* Number with percentage in brackets unless specified otherwise.

Table 2
Stereotactic radiosurgery treatment characteristics of the AVM.

| Treatment parameters               | Single fraction | 5 Fractions | Overall |
|------------------------------------|-----------------|-------------|---------|
| AVM volume, mL                     | 4.17 (2.19–9.2) | 22.3 (13.39–37.86) | 7.365 (2.53–12.71) |
| AVM location:\n Deep, n (%)        | 28 (22.05)      | 9 (20.93)   | 37 (21.76) |
| Non-deep, n (%)                    | 99 (77.95)      | 34 (79.07)  | 133 (78.24) |
| Prescribed dose, Gy                | 15 (15–16)      | 27.5 (25–28) | N/A     |
| Maximum dose, Gy                   | 25.4 (22.9–27.6) | 43.6 (38.2–45.3) | N/A     |
| Isodose line (%)                   | 60.63±6.11      | 64.19±6.11  | 61.52±6.32 |
| AVM coverage (%)                   | 94.82±0.72      | 94.82±0.64  | 94.82±0.70 |
| Conformity index                   | 1.3 (1.21–1.48) | 1.18 (1.14–1.22) | 1.23 (1.17–1.37) |

AVM = arteriovenous malformation, Gy = Gray, N/A = not applicable.
* The parameters are presented in median (interquartile range) or mean±standard deviation unless specified otherwise.
† Based on modified radiosurgery-based scoring system (deep AVM locations = brainstem, basal ganglion, and thalamus).51

With the median follow-up duration of 72.45 (60.7–91.8) months, 99 patients (58.24%) had complete AVM obliteration, confirmed by cerebral angiography in 72 (72.73%), and by MRI/MRA in 27 (27.27%) cases. The median time to obliteration was 39.4 (24.6–60.8) months (Table 3). The actuarial AVM obliteration rates from the single-fraction cohort, at 3, 5, 8, and 10 years, were 32.28%, 50.04%, 75.99%, and 75.99%, respectively. Patients with multisession CKSRS did not achieve the same level of success, evident by Log-rank test (Fig. 1), as the single-fraction treatment group (P < .001). Its actuarial post-SRS AVM obliteration rates were 9.3%, 11.75%, 31.6%, and 43%, at 3, 5, 8, and 10 years, respectively. No patient with AVM eradication suffered a new neurological deficit; hence, the rate of excellent outcome was maintained at 58.24% and none was classified into good or fair categories. Among the nonobliterated AVMs, 69 patients had no new deficit, resulting in the proportion of 40.59% for the unchanged outcome group. After CKSRS, 7

Figure 1. Kaplan-Meier curves demonstrating significantly different rates of arteriovenous malformation obliteration after single- vs 5-fraction CyberKnife stereotactic radiosurgery (CKSRS) treatments.
overall occurrences of AVM hemorrhage (4.12%), in 6 patients, were recorded. The events arose at as early as 6, but no later than 67 months after treatment (Fig. 2). Of the 6 patients, only 1 suffered a new neurological deficit with declined functional status. Apart from the hemorrhagic events, a 14-year-old girl developed glioblastoma multiforme (GBM), at the irradiated AVM region, 4 years after embolization and multisession CKSRS of her ruptured AVM. Surgical excision of the tumor was performed with subsequent chemotherapy and radiation. Although she did not have post-SRS hemorrhage or sustained a new neurological deficit, this patient and the aforementioned post-SRS hemorrhage victim were sorted into the same category, making the total number of 2 cases (1.18%) in the poor outcome group. Apart from the mentioned patients, the rest of the study cohort had no documented adverse radiation effect or death.

Table 4 details the patients’ and treatment’s variables for excellent outcome. The significant factors were the male sex ($P = .018$), AVM volume ($P = .021$), multisession SRS ($P < .001$), isodose line ($P = .018$), and time to AVM obliteration ($P < .001$).

In contrast to many publications, we did not find a history of AVM rupture ($P = .672$) or previous embolization ($P = .632$) to correlate with untoward results. Moreover, the age ($P = .908$) and deep location ($P = .338$) were not associated with excellent outcome, although the mRBAS appeared to be related ($P = .013$).

Further evaluation by uni- and multivariate analyses for independent predictors of excellent outcome was performed. The AVM volume (95% confidence interval [CI] = 0.98–1.04, $P = .488$), mRBAS (95% CI = 0.27–2.31, $P = .675$), and isodose line (95% CI = 0.91–1.02, $P = .272$) were insignificant, by multivariate examination, whereas the male sex (95% CI = 0.25–0.99, $P = .048$) and multisession SRS (95% CI = 0.06–0.57, $P = .003$) were confirmed to negatively affect the outcome (Table 5).

### 4. Discussion

Stereotactic radiosurgery is an established treatment modality for bAVM. Ideal SRS ought to yield high rates of AVM obliteration with a trivial proportion of complications. Despite advances in imaging studies and radiation delivery techniques, AVM obliteration rates remained relatively unchanged. However, newer technologies appeared to have lowered the overall sequelae of radiotherapy. Thanks to the frameless immobilization, CyberKnife SRS permits the option of administering treatment, by either single- or multisession, for varying sizes of AVMs. However, unlike ample data by GK and LINAC series, the literature search, for full-text documents published in the English language, produced just <10 publications from CK series. Moreover, there was only 1 publication that had a median follow-up duration >60 months. Unfortunately, only 9 patients comprised this published data by Gupta et al. Our study, therefore, included both the large number of AVM subjects and the long follow-up time. The overall AVM obliteration rate in this study was in line with the previously reported range of 50% to 90%, albeit on the lower end of the spectrum, possibly due to the lesser-than-average prescribed dose (15 Gy) along with the larger target volume. The overall rate of post-SRS hemorrhage was also within the reported 1% to 5% range.

Recognized negative factors, for AVM eradication by SRS, include patient factors, such as age, deep location, history of hemorrhage or large AVM volume, and treatment factors, that is, prescribed dose. This study concurred with previous publications with regard to the AVM volume and multisession SRS. It should reflect the substantial magnitude of targets that automatically mandated fractionation of radiotherapy rather than the poor selection of treatment options. On the other hand, the excellent outcome was not inversely affected by age, history of AVM rupture and deep location, as previous studies validating radiosurgery-based AVM scoring systems might suggest. Although most of the SRS series did not find sex to be associated with outcomes, this study, in a multivariate analysis, identified the male sex as an independent negative predictor. Frager et al published a similar observation and Bir et al found that female patients had a higher proportion of AVM obliteration. On the contrary, Yang et al found the male sex to be one of the protective factors against the post-SRS rebleeding and Liscak et al demonstrated that male patients achieved a higher percentage of AVM obliteration.

In addition to the above-mentioned negative factors, it is largely well-known that pre-SRS embolization hinders the probability of AVM obliteration. At Ramathibodi Comprehensive Neurovascular Center, there has always been a significant proportion of AVM patients whose pre-SRS embolization were necessary. In contrast, our statistical analysis contradicted those facts. Similar findings, of no untoward effect from prior embolization, were previously published by few centers. Oermann et al noted that the previously embolized AVMs had a significantly worse rate of obliteration after SRS. However, upon multivariate analysis, it failed to prove the case but, instead, the AVM architectural complexity was the actual negatively-affected variable. We have not explored this particular matter in the present study.

By not including abstract-only information, an English language literature search for full-text, from the PubMed, Scopus, and Google Scholar databases, returned 4 CKSRS for bAVM series with at least 20 cases. Despite the largest number of subjects in their study, Colombo et al performed the assessments of outcomes from 102 patients who had at least 36 months of follow-up. Therefore, with 170 AVMs and the
Table 4
Analyses of variables for excellent outcome by SRS treatment of brain AVM.

| AVMs | Total, n | Non-excellent outcome, n (%) | Excellent outcome, n (%) | P |
|------|----------|------------------------------|--------------------------|---|
| Patient factors | | | | |
| Sex | | | | |
| Female | 97 | 33 (46.48) | 64 (84.65) | .018 |
| Male | 73 | 38 (53.52) | 35 (50.00) | |
| Age, y, mean±SD | | | | |
| 34.28±14.42 | 34.03±13.72 | .008 |
| Presentation: | | | | |
| Hemorrhage (ruptured AVM) | 139 | 57 (80.28) | 82 (82.83) | .072 |
| Seizure | 29 | 12 (16.90) | 17 (17.17) | .853 |
| Asymptomatic | 2 | 1 (1.41) | 1 (1.01) | |
| Previous surgery | | | | |
| No | 163 | 69 (41.76) | 99 (58.24) | .701 |
| Yes | 7 | 2 (28.57) | 5 (62.50) | |
| Previous radiotherapy | | | | |
| No | 156 | 65 (41.18) | 91 (91.92) | .311 |
| Yes | 14 | 6 (42.86) | 8 (57.14) | |
| Previous embolization | | | | |
| No | 61 | 24 (33.80) | 37 (54.41) | .632 |
| Yes | 109 | 47 (66.20) | 62 (86.52) | |
| AVM volume, mL, median (IQR) | 7.4 (2.5–12.7) | 9.2 (3.1–16.3) | 4.9 (2.2–11.5) | .021 |
| AVM location: | | | | |
| Deep (brainstem, basal gangion, and thalamus) | 37 | 18 (25.35) | 19 (21.19) | .337 |
| Non-deep | 133 | 53 (74.65) | 80 (78.81) | |
| mRBAS, median (IQR) | 1.4 (0.9–2.0) | 1.6 (1.1–2.3) | 1.2 (0.8–1.9) | .013 |
| Treatment factors | | | | |
| SRS fractionation | | | | |
| Single fraction | 127 | 41 (57.75) | 86 (88.67) | <.001 |
| 5 Fractions | 43 | 30 (69.77) | 13 (29.77) | |
| Single-fraction prescribed dose, Gy, median (IQR) | 15 (15–16) | 15 (15–16) | 15 (15–16) | .997 |
| Single-fraction maximum dose, Gy, median (IQR) | 25.4 (22.9–27.6) | 24.2 (22.4–27.3) | 25.4 (23.3–27.7) | .254 |
| 5-Fraction prescribed dose, Gy, median (IQR) | 27.5 (25–28) | 26.7 (25–28) | 27.5 (25–28) | .145 |
| 5-Fraction maximum dose, Gy, median (IQR) | 43.5 (38.2–44.8) | 43.6 (37.9–45.3) | 43.1 (42.2–44.8) | .853 |
| Isodose line, % mean±SD | 61.52±6.32 | 62.87±6.76 | 60.56±5.83 | .018 |
| AVM coverage, %, mean±SD | 94.82±0.70 | 94.88±0.85 | 94.77±0.57 | .347 |
| Conformity index, median (IQR) | 1.2 (1.2, 1.4) | 1.2 (1.2, 1.3) | 1.2 (1.2, 1.4) | .320 |
| Time to AVM obliteration, mo, median (IQR) | 60.4 (30.5–75.2) | 76.0 (60.8–106.1) | 39.4 (24.6–60.8) | <.001 |

AVM = arteriovenous malformation, Gy = Gray, IQR = interquartile range, m = month, mRBAS = modified radiosurgery-based AVM score, N/A = not applicable, SD = standard deviation, SRS = stereotactic radiosurgery, y = year.
* Number with percentage in brackets unless specified otherwise.

Table 5
Regression analyses of the predictors for excellent outcome by SRS treatment of brain AVM.

| | Univariate analysis | | Multivariate analysis | |
|-----------------|---------------------|-----------------------|-----------------------|
| | Odds ratio (95% CI) | P | Odds ratio (95% CI) | P |
| Patient factors | | | | |
| Sex, male | 0.474 (0.25–0.88) | .019 | 0.505 (0.25–0.99) | .048 |
| Age | 0.998 (0.97–1.02) | .908 | | |
| AVM volume | 0.973 (0.95–0.99) | .023 | 1.010 (0.98–1.04) | .488 |
| Deep AVM locations | 0.699 (0.34–1.45) | .338 | | |
| mRBAS | 0.770 (0.62–0.95) | .019 | 0.796 (0.27–2.31) | .675 |
| Previous hemorrhage (ruptured AVM) | 1.184 (0.54–2.59) | .672 | | |
| Previous embolization | 0.855 (0.45–1.62) | .632 | | |
| Treatment factors | | | | |
| Multisession SRS | 0.206 (0.09–0.43) | <.001 | 0.185 (0.06–0.57) | .003 |
| Isodose line | 0.942 (0.89–0.99) | .020 | 0.969 (0.91–1.02) | .272 |

Cl = confidence interval, mRBAS = modified radiosurgery-based AVM score, deep AVM locations = brainstem, basal ganglion, and thalamus, SRS = stereotactic radiosurgery.

Cl = confidence interval, mRBAS = modified radiosurgery-based AVM score.
The median follow-up duration of 72.45 months, our study represents the largest cohort demonstrating long-term results among the published series of frameless image-guided robotic SRS for bAVM (Table 6). Although the overall AVM obliteration from our study, compared with others, appeared to be relatively low, there are several conceivable explanations for it. First, the median AVM volume of 4.17 mL in the single-fraction group was the largest among the CKSRS series. In addition, this study comprised a higher proportion of larger AVMs than other CK series, with the median volume of 22.3 mL. Due to sizeable AVMs, the prescribed doses for single- and multisession CKSRS were relatively lower than in other studies. Considering this, lower than average obliteration rates were rather predictable. Nevertheless, the incidence of post-SRS AVM hemorrhage appeared to be within the reported range. 

Table 6

| Parameters | Colombo et al.[14] 2009 | Wowra et al.[17] 2009 | Oermann et al.[18] 2014 | Feutren et al.[19] 2018 | Present study |
|------------|------------------------|------------------------|------------------------|------------------------|--------------|
| No. of patients treated with CKSRS | 279 | 20 | 26 | 48 | 277 |
| No. of patients with follow-up | 267 | 20 | 26 | 48 | 255 |
| No. of patients with follow-up >36 mo | 102 | NS | NS | 33 | 166 Patients, 170 AVMs |
| Follow-up duration, mo | 31 | 25 | 25 | 41 | 72.45 |

Patient characteristics

| Age, y | 34 | 33.4 | 41 | 32 | 26.5 |

| Patients with AVM rupture (hemorrhage), n (%) | 45 (44.12) | 9 (45) | 14 (54) | 19 (39.58) | 139 (81.76) |

Proportion of patients with previous embolization (%) | 50 | 30 | 42.3 | 85.42 | 64.12 |

Overall AVM obliteration rate (%) | 71.5 | 67 | 57.69 | 68 | 58.24 |

RBAS (median) | 1.41 | 1.35 | NS | 1.24 | 1.4 (mRBAS) |

<1, n (%) | 17 (16.67) | NS | NS | 14 (29.2) | 47 (27.65) |

1.01–1.5, n (%) | 37 (36.27) | NS | NS | 26 (54.2) | 48 (28.24) |

1.51–2, n (%) | 30 (29.41) | NS | NS | 7 (14.5) | 32 (18.82) |

>2, n (%) | 18 (17.65) | NS | NS | 1 (2.15) | 43 (25.29) |

Treatment parameters

Proportion of patients treated with single-fraction CKSRS (%) | 79.41 | 100 | 100 | 100 | 74.71 |

**Outcome (%)**

| Excellent | NS | NS | NS | NS | 58.24 |
| Good | NS | NS | NS | NS | 0 |
| Fair | NS | NS | NS | NS | 0 |
| Unchanged | NS | NS | NS | NS | 40.59 |
| Poor | NS | NS | NS | NS | 1.18 |
| Death | 0 | 0 | 0 | 0 | 0 |

Remarks 1 Patient with new deficit 1 Patient with new deficit 3 Patients with motor deficit 2 Patients with grade 4 symptomatic ARE 1 Patient with GBM and 1 patient with new deficit

Overall post-CKSRS hemorrhage (%) | 8 (3) | 1 (5) | 1 (3.8) | NS | 4 (1.42) |

| ARE = adverse radiation effect, AVM = arteriovenous malformation, CKSRS = CyberKnife stereotactic radiosurgery, GBM = glioblastoma multiforme, m = month, mL = milliliter, mRBAS = modified RBAS, NS = not specified, RBAS = radiosurgery-based arteriovenous malformation score[20]. |
| * The parameters are presented in median unless specified otherwise. |
| † Outcome report from Colombo et al.[14] derived from 102 patients with follow-up >36 months. |
| ‡ Post-CKSRS hemorrhage from Colombo et al.[14] was calculated from 8 incidences of 267 patients. |

Post-SRS AVM rebleeding. None detailed their results based on RBAS or mRBAS systems; hence, this study was the first, among CKSRS cohorts, to stratify results by standardized method. One patient with GBM was observed in the study. She was the second case who developed this malignancy after CKSRS for bAVM, after the first patient report from Xhumari et al.[37]

5. Study limitations

The presented study has some limitations. First, the “criterion standard” cerebral angiography to determine complete obliteration was not used in all cases. Due to the fact that some patients refused to take part in the post-SRS cerebral angiographic study, the outcome assessment is less than ideal because of the nonuniform post-treatment radiographic evaluation. Another constraint was the exclusion of 111 cases (39%) for lack of data or insufficient follow-up duration. It could have affected the overall obliteration rate or the incidence of complications as
shown by Heffez et al. However, these limitations are common hindrances associated with retrospective reviews.

6. Conclusion

These results, with a considerable number of patients and extensive follow-up duration, confirmed the efficacy and safety of the frameless image-guided robotic stereotactic radiosurgery for brain AVM. Identified risk factors hindering achievement of excellent outcome were the male sex and multisession treatment.

Acknowledgments

The authors thank Miss Suraida Aeesoa for her assistance in statistical analyses of the study and Dr. Nattaphong Rattanavottkul for manuscript corrections.

Author contributions

Conceptualization: Pritsana Punyawai, Mantana Dhanachai, Chai Kobkitsuksakul, Ake Hansasuta.

Data curation: Pritsana Punyawai, Nicha Radomsutthikul.

Formal analysis: Pritsana Punyawai, Ake Hansasuta.

Investigation: Pritsana Punyawai, Nicha Radomsutthikul.

Methodology: Pritsana Punyawai, Mantana Dhanachai, Ake Hansasuta.

Project administration: Ake Hansasuta.

Supervision: Mantana Dhanachai, Chai Kobkitsuksakul, Ake Hansasuta.

Validation: Pritsana Punyawai, Ake Hansasuta.

Writing – original draft: Pritsana Punyawai, Ake Hansasuta.

Writing – review & editing: Mantana Dhanachai, Ake Hansasuta.

References

[1] van Beijnum J, van der Worp HB, Buus DR, et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA 2011;306:2011–9.

[2] Solomon RA, Connolly ES Jr. Arteriovenous malformations of the brain. N Engl J Med 2017;376:1839–66.

[3] Liscak R, Vladyka V, Simonova G, et al. Arteriovenous malformations after Leksell gamma knife radiosurgery: rate of obliteration and complications. Neurosurgery 2007;60:1003–14. discussion 1015-1006.

[4] Jokura H, Kawagishi J, Sugai K, et al. Gamma knife radiosurgery for arteriovenous malformations: the Furukawa experience. Prog Neurol Surg 2009;22:20–30.

[5] Paul L, Casasco A, Kusak ME, et al. Results for a series of 697 arteriovenous malformations treated by gamma knife: influence of angiographic features on the obliteration rate. Neurosurgery 2014;75:568–83. discussion 582-563; quiz 583.

[6] Cohen-Inbar O, Lee CC, Xu Z, et al. A quantitative analysis of adverse radiation effects following Gamma Knife radiosurgery for arteriovenous malformations. J Neurosurg 2015;123:945–53.

[7] Starke RM, Kano H, Ding D, et al. Stereotactic radiosurgery for cerebral arteriovenous malformations: evaluation of long-term outcomes in a multicenter cohort. J Neurosurg 2017;126:36–44.

[8] Pollock BE. Gamma knife radiosurgery of arteriovenous malformations: long-term outcomes and late effects. Prog Neurol Surg 2019;34:238–47.

[9] Friedman WA, Bova FJ, Mendenhall WM. Linear accelerator radiosurgery for arteriovenous malformations: the relationship of size to outcome. J Neurosurg 1995;82:180–9.

[10] Schlinger M, Atlan D, Lefkopoulos D, et al. Linac radiosurgery for cerebral arteriovenous malformations: results in 169 patients. Int J Radiat Oncol Biol Phys 2000;46:1135–42.

[11] Bollet MA, Anzionnat R, Buchheit I, et al. Efficacy and morbidity of arc-therapy radiosurgery for cerebral arteriovenous malformations: a comparison with the natural history. Int J Radiat Oncol Biol Phys 2004;58:1353–63.

[12] Raffa SJ, Chi YY, Bova FJ, et al. Validation of the radiosurgery-based arteriovenous malformation score in a large linear accelerator radiosurgery experience. J Neurosurg 2009;111:810–9.

[13] Fokas E, Henzel M, Wittig A, et al. Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. J Neurol 2013;260:2156–62.

[14] Colombo F, Cavedon C, Casentini L, et al. Early results of CyberKnife radiosurgery for arteriovenous malformations. J Neurosurg 2009;111:807–19.

[15] Gupta R, Moore JM, Amorin A, et al. Long-term follow up data on difficult to treat intracranial arteriovenous malformations treated with the CyberKnife. J Clin Neurosci 2019:61:120–3.

[16] Ding C, Solberg TD, Hrycushko B, et al. Multi-staged robotic stereotactic radiosurgery for large cerebral arteriovenous malformations. Radiother Oncol 2013;109:452–6.

[17] Wowra B, Muezevic A, Tonon JG, et al. Obliteration dynamics in cerebral arteriovenous malformations after Cyberknife radiosurgery: quantification with sequential nidus volumetry and 3-tesla 3-dimensional time-of-flight magnetic resonance angiography. Neurosurgery 2009;64(2 suppl): A102–9.

[18] Oerermann EK, Murthy N, Chen V, et al. A multicenter retrospective study of frameless robotic radiosurgery for intracranial arteriovenous malformation. Front Oncol 2014;4:298.

[19] Feutren T, Huertas A, Salleron J, et al. Modern robot-assisted radiosurgery of cerebral angiomas-own experiences, system comparisons, and comprehensive literature overview. Neurosurg Rev 2018;41:787–97.

[20] Pollock BE, Flickinger JC. Modification of the radiosurgery-based arteriovenous malformation grading system. Neurosurgery 2008;63:239–43, discussion 243.

[21] Pollock BE, Flickinger JC. A proposed radiosurgery-based grading system for arteriovenous malformations. J Neurosurg 2002;96:79–85.

[22] Patibandla MR, Ding D, Kano H, et al. Effect of treatment period on outcomes after stereotactic radiosurgery for brain arteriovenous malformations: an international multicenter study. J Neurosurg 2018;1:10.

[23] Zabel A, Milker-Zabel S, Huber P, et al. Treatment outcome after linac-based radiosurgery in cerebral arteriovenous malformations: retrospective analysis of factors affecting obliteration. Radiother Oncol 2005;77:105–10.

[24] Tashob Meybodi A, Lawton MT. Modern radiosurgical and endovascular classification schemes for brain arteriovenous malformations. Neurosurg Rev 2020;43:49–58.

[25] Vlaskou Badra E, Ermis E, Mordasinpi P, et al. Radiosurgery and radiotherapy for arteriovenous malformations: outcome predictors and review of the literature. J Neurosurg Sci 2018;62:490–504.

[26] Pollock BE. Development and testing of a radiosurgery-based arteriovenous malformation grading system. Prog Neurol Surg 2013;27:58–66.

[27] Starke RM, Yen CP, Ding D, et al. A practical grading scale for predicting outcome after radiosurgery for arteriovenous malformations: analysis of 1012 treated patients. J Neurosurg 2013;119:981–7.

[28] Pollock BE, Storlie CB, Link MJ, et al. Comparative analysis of arteriovenous malformation grading scales in predicting outcomes after stereotactic radiosurgery. J Neurosurg 2017;126:852–8.

[29] Frager MJ, Glazener EM, Rahimian J, et al. A comparative outcomes analysis of patients treated for arteriovenous malformation with LINAC-based stereotactic radiosurgery by a standard frame-based technique or a frameless technique utilizing 3-dimensional rotational angiography. J Clin Neurosci 2020;77:185–90.

[30] Bit SC, Ambekar S, Mani TK, et al. Clinical outcome and complications of gamma knife radiosurgery for intracranial arteriovenous malformations. J Clin Neurosci 2015;22:1117–22.

[31] Yang W, Lukisik AS, Jiang B, et al. Venous stenosis and hemorrhage after radiosurgery for cerebral arteriovenous malformations. World Neurosurg 2019;122:e1615–25.

[32] Russell D, Peck T, Ding D, et al. Stereotactic radiosurgery alone or combined with embolization for brain arteriovenous malformations: a systematic review and meta-analysis. J Neurosurg 2018;128:1338–48.
[33] Zhu D, Li Z, Zhang Y, et al. Gamma knife surgery with and without embolization for cerebral arteriovenous malformations: A systematic review and meta-analysis. J Clin Neurosci 2018;56:67–73.

[34] Lee CC, Chen CJ, Ball B, et al. Stereotactic radiosurgery for arteriovenous malformations after Onyx embolization: a case-control study. J Neurosurg 2015;123:126–35.

[35] Izawa M, Chernov M, Hayashi M, et al. Combined management of intracranial arteriovenous malformations with embolization and gamma knife radiosurgery: comparative evaluation of the long-term results. Surg Neurol 2009;71:43–52, discussion 52-43.

[36] Oermann EK, Ding D, Yen CP, et al. Effect of prior embolization on cerebral arteriovenous malformation radiosurgery outcomes: a case-control study. Neurosurgery 2015;77:406–17, discussion 417.

[37] Xhumari A, Rroji A, Enesi E, et al. Glioblastoma after AVM radiosurgery. Case report and review of the literature. Acta Neurochir (Wien) 2015;157:889–95.

[38] Heffez DS, Osterdock RJ, Alderete L, et al. The effect of incomplete patient follow-up on the reported results of AVM radiosurgery. Surg Neurol 1998;49:373–81, discussion 381–374.